Dutch Government to Donate $1.5M to Fund CBD, Epilepsy Study

Dutch Government to Donate $1.5M to Fund CBD, Epilepsy Study

The UMC Utrecht Brain Center will receive approximately $1.5 million (€1.4 million) from the Dutch government in collaboration with various Dutch organizations. Bedrocan published his study on March 20. Previous studies have shown that CBD reduced seizures in children. Certain epilepsy-related syndromes.

UK based CAnavis Health News report Via Government or ZonMW Appropriate Drug Use Programresearchers will use the funds to launch a four-year research project that will delve into the effects of high CBD oil on children with severe epilepsy.

Researchers administer Bedrolite, a whole plant high-CBD oil from Transvaal Pharmacy in the Netherlands, made using cannabis produced by Bedrocan. There will be 50 participants in the trial, which is scheduled to start in the summer. The first patients are expected to start by the end of the year.

Researchers will study whether this oil is effective in reducing the frequency of sensitivities. seizureThey also measured seizure length, sleepy, and arousal.Patient must have no previous use CBD oil A minimum of 8 seizures every 4 weeks is required for treatment of epilepsy and/or seizures.

“Our research is individual-focused. Instead of looking at groups, we look at individual patients to see if a drug works,” said lead investigator Floor Jansen, a pediatric neurologist. increase. “We would like to investigate whether the number of seizures is reduced, but we are also keeping an eye on other important outcomes for patients: reducing the use of emergency medications for prolonged seizures, changes in attention, nighttime Think about improving your sleep.”

Rare and intractable epilepsy is understudied. Researchers look at individual cases rather than whole groups to determine whether a drug works for each patient.

Intractable epilepsy It is a charity that raises funds to help families pay for private cannabis prescriptions. Jo Griffiths, chairman of Refractory Epilepsy, said he hopes the UK will match up to €1.4 million for a randomized controlled trial (RCT) of his Bedrocan product.

“Refractory epilepsy will support families with private medical cannabis costs if prescribed for at least six months,” Griffiths said. We can’t even afford it: To ensure that all children and young adults with intractable epilepsy have access to full extract medicinal cannabis, governments and health care providers say a gold-standard RCT is needed. We are therefore asking the UK government to use the Dutch government’s €1.4m for trials and to conduct NHS trials using the same oil.”

“The NHS has prescribed the exact same oil to two children in the UK over the past four years, while others have paid for it privately and some families have turned to the unregulated black market.” she said.

Alongside RCTs, Refractory Epilepsy calls for observational studies to examine the effects of whole plant cannabis oil on people who have already found success with compounds.

“Alongside the UK RCT, we would love to see an observational trial recommended by the Health Choices Commission in 2019 for people already taking full extract oils,” she added.

“It would be prudent for the government and the NHS to participate in these trials to build an evidence base that has proven more than 50 children in the last four years.”

The study will begin this summer, with the first patients expected to receive treatment by the end of 2023.

David B.
David B. stands out as an exceptional cannabis writer, skillfully navigating the intricate world of cannabis culture and industry. His insightful and well-researched articles provide a nuanced perspective on various aspects, from the therapeutic benefits to the evolving legal landscape. David's writing reflects a deep understanding of the plant's history, its diverse strains, and the ever-changing dynamics within the cannabis community. What sets him apart is his ability to break down complex topics into digestible pieces, making the information accessible to both seasoned enthusiasts and newcomers alike. With a keen eye for detail and a passion for the subject, David B. emerges as a reliable and engaging voice in the realm of cannabis literature.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *